Pharmafile Logo

Insight Gathering for Life Science Companies

Virtual engagement experts helping life science companies have ongoing conversations with their customers through our best-in-class online collaboration tools. Best-In-Class CollaborationTechnology
Impetus Digital provides two turn-key software solutions through the Impetus InSite Platform®: InSite Touchpoints™and InSite Events™, that create flawless online experiences by leveraging our award-winning synchronous and asynchronous tools and services.Our team of experts will take on the stress of event planning and management by providing you with tailored white-glove service to ensure your event’s success. Our platform is fully customizable, multilingual, and equipped with robust, pharma-compliant security that make it the ideal choice for authentic engagement.The Impetus InSite Platform® is highly customizable and has endless use cases:Virtual advisory boardsCongresses and conferencesMedical education and trainingSteering committeesCorporate meetingsCo-author working groupsPatient journey mappingTreatment pathway profilingVirtual journal clubsConference debrief sessionsGrant review programsResource hubsFishbowl web meetingsOngoing discussion forumsCase study submissionsOnline debatesVirtual hackathonsAnd much more!Subscribe to our channel to get the latest insights from leaders in the pharmaceutical, healthcare and biotech industries!

To learn more, visit us at http://impetusdigital.com/Book a demo today http://www.meetwithimpetus.com/  


This content was provided by Impetus Digital

Company Details

 Latest Content from  Impetus Digital 

Patient Advocate Engagement: A Customer Story

Learn how our client executed a series of 3 virtual touchpoints with 5 rare disease patient advocates to:- Develop a better understanding of the current treatment landscape and lived patient...

Tailored Marketing Strategies for Pharma – Top 10 Most Important Advisor Questions

In this video, we explore another crucial aspect of advisor questions when developing your virtual advisory board touchpoints – a key component for success in today's diverse healthcare landscape. 7....

Trends in Virtual Collaboration

Join us for a look at the top-5 emerging virtual collaboration trends...

Advisor Questions on Potential Data or Knowledge Gaps

As part of our top 10 most important advisor questions that every brand team should keep in mind when designing virtual advisory board touchpoints, here's another one to keep in...

On a journey to diverse, inclusive, and more efficient rare disease trials

Although orphan drugs represent a sizeable portion of new drug approvals, most rare diseases still lack effective treatment. Even more so than for other conditions, rare disease management contains large care...

Versatility! Top 10 benefits of virtual advisory boards

Here's another great tip on why the benefits of virtual advisory boards are superior to in-person and hybrid advisory boards. #10. Versatility! Another major advantage of using a virtual platform...

Clinical Trials Investigator and Patient Engagement Planning: A Customer Story

In the early lead-up to our client’s multi-center Rare Disease Phase 3 Clinical Trial, they first conducted an internal engagement planning Longitudinal Expert Engagement Plan™ (LEEP™) to conduct an informal...

New Playbook Alert: Virtual Patient Engagement

Authentic patient engagement and insight-gathering are becoming must-haves in Pharma. However, multiple obstacles remain before patient-centricity becomes more than a buzzword. In our latest playbook, we take a deep dive...

No “White Space” Between Live Meetings; the top 10 benefits of virtual advisory boards

Here's another great tip on why the benefits of virtual advisory boards are superior to in-person and hybrid advisory boards. #9. No More “White Space” Between Live Meetings Clearly, the...

The problem with clinical trials (and how virtual insight-gathering can help)

While still the gold standard of research, clinical trials are often riddled with issues that limit their applicability to broader populations or delay market access.